Beijing Cell-fusion Biotechnology

Beijing Saifu Pharmaceutical Technology (Saifu), also known as Beijing Cell-fusion Biotechnology, is a leading Chinese Contract Research Organization (CRO) providing comprehensive pre-clinical and clinical research services. Founded in 2016 and headquartered in Beijing, the company specializes in toxicology, safety evaluation, pharmacology, and efficacy studies for a wide range of therapeutic modalities, including small molecules, biologics, and advanced cell and gene therapies. Saifu operates multiple GLP-compliant facilities across China and offers integrated services from drug discovery support and antibody development to Phase I clinical trials. The company is recognized for its expertise in innovative drug evaluation and has established a strong reputation as a "one-stop" service provider for the global biopharmaceutical industry.